Venus Remedies Reports Strong Financial Growth and Improved Profitability in May 2025 Results

Venus Remedies, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending March 2025. The results, declared on May 26, 2025, indicate a notable shift in the company's evaluation, with its score rising to 19 from 11 over the past three months. The financial performance showcases significant growth in key metrics. The Profit After Tax (PAT) reached Rs 21.00 crore, reflecting a substantial year-on-year growth of 99.8%. Similarly, the Profit Before Tax less Other Income (PBT) stood at Rs 24.28 crore, marking a year-on-year increase of 79.32%. The Operating Profit (PBDIT) also reached its highest level in the last five quarters at Rs 29.00 crore, indicating a positive trend in operational efficiency, as evidenced by an Operating Profit Margin of 14.87%, the best in the same timeframe. Additionally, the Earnings per Share (EPS) hit Rs 15.71, the highest recorded in the last five quarters, suggesting enhanced profitability and value creation for shareholders. These results reflect a robust performance trajectory for Venus Remedies in the recent quarter. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.